“…L-Asparaginase (EC 3.5.1.1) has been used as therapeutic remedy for acute lymphoblastic leukemia (ALL) wherein lymphoblasts are auxotrophic for L-asparagine, and the enzyme diminishes the supply of exogenous asparagine, thus forcing the tumor cells into apoptosis. 1,2 The antineoplastic activity of Lasparaginase has been explored from microbial sources such as Escherichia coli, 3,4 Proteus vulgaris, 5 Serratia marcescens, 6,7 Bacillus sp., 8 Pseudomonas aeruginosa, 9 Streptomyces sp., 10,11 Aspergillus terreus, 12 and Erwinia carotovora. 13 The substrate specicity of L-asparaginase is characterized for both L-asparagine and L-glutamine where L-glutamine differs from L-asparagine by a single methyl group, consequently Lasparaginase treatment diminishes L-glutamine availability along with the concentration of L-asparagine, causing side effects like leucopenia, acute pancreatitis, hyperglycemia and neurological seizures in ALL patients.…”